SUNNYVALE, Calif., 3 & # 39; December 2018 / PRNewswire / – NeuCyte, Inc., parent company of drug discovery of neuroscience, announced that it entered a & # 39; license agreement with Children's Hospital & # 39; Boston. As part of the agreement, Boston Children & # 39; s obtained an exclusive license from NeuCyte to manufactures feature & # 39; transcript Ngn2 neurons induced programmed. The hospital intends to use this technology for internal research, educational and educational purposes, and to perform other services to academic institutions.
"We are pleased to deny this advantageous technology originated from laboratory & # 39; Dr. Thomas Südhof in Stanford University, "Said Mustafa Sahin, MD, PhD, director of the Center of & # 39; translational Neuroscience and Human neuron at Core & # 39; Tank & # 39; Boston and professor & # 39; in neurology Medical School & # 39; Harvard. "We hope that this technology allows us and other researchers to create a tool that resembles human biology in vitro and will become an important part of our effort to improve human health. "
"NeuCyte has exclusive rights Stanford & # 39; s original technology & # 39; neuronal induction and further developed to incorporate into our property in vitro platforms for drug discovery ", said Jonathan Davila, PhD, co-founder and CEO & # 39; NeuCyte. "We are pleased to have technology in & # 39; the Children's Hospital hands & # 39; Boston where you & # 39; is used more for academic research. We also welcome discussions with & # 39; other organizations interested in & # 39; this technology. "
About NeuCyte, Inc.
NeuCyte is an innovative biotechnology company focused on the development of & # 39; medicines that have an impact to improve the lives of & # 39; patients suffering from neurological disorders. Based on proprietary technology SynFire ® to generate neural cells induced derived from human b & # 39; induced pluripotent stem cells (IPSC), NeuCyte developed in vitro platform with & # 39; high function for the identification and validation -mira, testing effectiveness, neurotoxicity assessment and disease modeling. With vast knowledge brought by the staff and board & # 39; his scientific advice, NeuCyte pursuing b & # 39; actively programs & # 39; drug discovery for the treatment of & # 39; Fragile X Syndrome, Epilepsy, ALS and more.
1230 Bordeaux Drive
Sunnyvale, CA 94089
SOURCE & # 39; NeuCyte, Inc.